Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 1, 2018, Pages 123-128

  Cacoub, P ^a,b,c   Vautier, M ^a,b   Desbois, A C ^a,b,c   Saadoun, D ^a,b,c   Younossi, Z ^d,e  

^a SORBONNE UNIVERSITÉ   (France)

^b Unit of Dermatology   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INOVA FAIRFAX HOSPITAL   (United States)

^e BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CRYOGLOBULINEMIA; DEPRESSION; DIABETES MELLITUS; END STAGE RENAL DISEASE; EXTRAHEPATIC MANIFESTATION; FRANCE; GLOMERULONEPHRITIS; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; HEART FAILURE; HEART INFARCTION; HEPATITIS C; HUMAN; LICHEN PLANUS; LYMPHOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMATIC REVIEW; TERTIARY HEALTH CARE; VASCULITIS; COMPLICATION; ECONOMICS; EPIDEMIOLOGY; HEPACIVIRUS; ISOLATION AND PURIFICATION; RETROSPECTIVE STUDY;

CRYOGLOBULINEMIA; FRANCE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C; HUMANS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 85031495067     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14382     Document Type: Article

References (31)

1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135.
2. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42:2204-2212.
3. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14.
4. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2-17.
5. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165-S173.
6. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol. 2015;7:327-343.
7. Cheng Z, Zhou B, Shi X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl). 2014;127:1206-1210.
8. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544-563.
9. Henry L, Younossi Z. Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2016;16:659-665.
10. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530-537.
11. Rotily M, Vainchtock A, Jouaneton B, Wartelle-Bladou C, Abergel A. How did chronic hepatitis C impact costs related to hospital health care in France in 2009? Clin Res Hepatol Gastroenterol. 2013;37:365-372.
12. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599-1608.
13. https://www.vidal.fr/fiches-medicaments. Accessed October 13, 2016.
14. http://www.insee.fr/fr/themes/indicateur.asp?id=29&page=series_ipc.htm. Accessed October 13, 2016.
15. Pioche C, Pelat C, Larsen C, et al. Estimation de la prévalence de l'hépatite C en population générale, France métropolitaine, 2011. Bull Epidémiol Hebd. 2016;13–14:224-229.
16. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatol Baltim Md. 2016;64:1473-1482.
17. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatol Baltim Md. 2016;63:408-417.
18. Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777-1782.
19. Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol. 2002;36:812-818.
20. Hsu Y-C, Lin J-T, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302.
21. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.
22. Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61:128-134.
23. Ward JW, Mermin JH. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med. 2015;373:2678-2680.
24. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236.
25. Résultats desLes dépenses de santé en 2014 - Comptes de la santé - Comptes nationaux de la santé - Ministère des Affaires sociales et de la Santé [Internet]. http://drees.social-sante.gouv.fr/etudes-et-statistiques/publications/recueils-ouvrages-et-rapports/recueils-annuels/comptes-nationaux-de-la-sante/article/les-depenses-de-sante-en-2014-resultats-des-comptes-de-la-sante. Accessed août 23, 2016.
26. Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol. 2016;40:340-348.
27. Visentini M, Colantuono S, Granata G, de Santis A, Fiorilli M, Casato M. The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy. Hepatol Baltim Md. 2015;62:975.
28. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516.
29. Cacoub P, Vautier M, Desbois AC, Lafuma A, Saadoun D. Effectiveness and cost of hepatitis C virus cryoglobulinemia vasculitis treatment: from interferon-based to direct-acting antivirals. Liver Int. 2017; https//doi.org/10.1111/liv.13465 [Epub ahead of print].
30. Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42:2383-2391.
31. Lee M-H, Yang H-I, Lu S-N, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469-477.